Tom Gallagher
Senior Editor
Tom runs the editorial calendar and writes when a topic needs a no nonsense treatment. Twenty years in publishing taught him that readers reward clarity and punish padding.
Oral Semaglutide Uptake Tracked After Approval
A new analysis looks at how quickly patients started oral semaglutide for obesity once it reached pharmacies.
Tirzepatide Research Overview: What Studies Show About This Dual GIP/GLP-1 Agonist
A plain look at what clinical trials actually show about tirzepatide, the dual GIP and GLP 1 agonist.
FDA Approves Camzyos for Children With Obstructive HCM
FDA approved Camzyos for pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy, extending its 2022 adult approval.
Follistatin 344 Research Overview: What Studies Show About This Myostatin Inhibiting Peptide
A plain look at what preclinical and case report data actually say about follistatin 344 and myostatin inhibition.
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
FDA clears Fayuvi, a one time gene therapy for pediatric MPS IIIA, based on a single arm study versus historical controls.
Semax and Selank: Cognitive Peptide Research
Semax and Selank are Russian developed peptides studied for cognition and stress, with animal data far ahead of human trials.
FDA Panel Backs BPC-157 and TB-500 for Compounding
An FDA panel recommended BPC-157 and TB-500 for a compounding list. That is not drug approval.